UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

How to improve R&D productivity: the pharmaceutical industry's grand challenge

Nature reviews. Drug discovery, 2010-03, Vol.9 (3), p.203-214

2010

Link zum Volltext

Verfügbarkeit prüfen

MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model

Stem cell research & therapy, 2021-01, Vol.12 (1), p.72-72, Article 72

2021

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis

Multiple sclerosis, 2023-01, Vol.29 (1), p.92-106

2023

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis

The American journal of psychiatry, 2006-05, Vol.163 (5), p.790-799

2006

Link zum Volltext

Verfügbarkeit prüfen

Covariate‐adjusted borrowing of historical control data in randomized clinical trials

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2017-07, Vol.16 (4), p.296-308

2017

Link zum Volltext

Verfügbarkeit prüfen

Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivity

Nature reviews. Drug discovery, 2014-08, Vol.13 (8), p.638-640

2014

Link zum Volltext

Verfügbarkeit prüfen

Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome

Biological psychiatry (1969), 2003-08, Vol.54 (4), p.453-464

2003

Link zum Volltext

Verfügbarkeit prüfen

Multiple imputation techniques in small sample clinical trials

Statistics in medicine, 2006-01, Vol.25 (2), p.233-245

2006

Link zum Volltext

Verfügbarkeit prüfen

Calming versus sedative effects of intramuscular olanzapine in agitated patients

The American journal of emergency medicine, 2003-05, Vol.21 (3), p.192-198

2003

Link zum Volltext

Verfügbarkeit prüfen

Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol

Psychopharmacology, 2003-09, Vol.169 (3-4), p.390-397

2003

Link zum Volltext

Verfügbarkeit prüfen

A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy

Clinical therapeutics, 2003-05, Vol.25 (5), p.1420-1428

2003

Link zum Volltext

Verfügbarkeit prüfen

The impact of missing data and how it is handled on the rate of false-positive results in drug development

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2008-07, Vol.7 (3), p.215-225

2008

Link zum Volltext

Verfügbarkeit prüfen

Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients

Psychiatry research, 2003-07, Vol.119 (1), p.113-123

2003

Link zum Volltext

Verfügbarkeit prüfen

Intramuscular Olanzapine and Intramuscular Haloperidol in Acute Schizophrenia: Antipsychotic Efficacy and Extrapyramidal Safety during the First 24 Hours of Treatment

Canadian journal of psychiatry, 2003-12, Vol.48 (11), p.716-721

2003

Link zum Volltext

Verfügbarkeit prüfen

Evidence for Onset of Antipsychotic Effects Within the First 24 Hours of Treatment

The American journal of psychiatry, 2005-05, Vol.162 (5), p.939-946

2005

Link zum Volltext

Verfügbarkeit prüfen

Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials

Multiple sclerosis and related disorders, 2020-04, Vol.39, p.101865-101865, Article 101865

2020

Link zum Volltext

Verfügbarkeit prüfen

Panel discussion 2

Clinical trials (London, England), 2012-12, Vol.9 (6), p.736-740

2012

Link zum Volltext

Verfügbarkeit prüfen

A Portfolio-Based Approach to Optimize Proof-of-Concept Clinical Trials

Journal of biopharmaceutical statistics, 2012-05, Vol.22 (3), p.596-607

2012

Link zum Volltext

Verfügbarkeit prüfen

Bayesian adaptive non-inferiority with safety assessment: Retrospective case study to highlight potential benefits and limitations of the approach

Journal of psychiatric research, 2009-02, Vol.43 (5), p.561-567

2009

Link zum Volltext

Verfügbarkeit prüfen

Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol: Special Issue on Cognition in Schizophrenia: from basic science to clinical treatment

Psychopharmacologia, 2003, Vol.169 (3-4), p.390-397

2003

Link zum Volltext

Verfügbarkeit prüfen

Influencing-Even Without Statistics

Chance (New York), 2014-10, Vol.27 (4), p.26-27

Lindborg, Stacy R.

2014

Link zum Volltext

Verfügbarkeit prüfen

Statistical issues: a roundtable discussion

Clinical trials (London, England), 2005-08, Vol.2 (4), p.364-372

2005

Link zum Volltext

Verfügbarkeit prüfen

Practical Considerations for Building Priors for Confirmatory Studies

Bayesian Applications in Pharmaceutical Development, 2020, p.49-59

1, 2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(25)

Publikationsform

Sprache

Englisch
(27)
Japanisch
(8)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

How to improve R&D productivity: the pharmaceutical industry's grand challenge

A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis

MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model

Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis

Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes

Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis

Covariate‐adjusted borrowing of historical control data in randomized clinical trials

Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivity

Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome

Multiple imputation techniques in small sample clinical trials

Calming versus sedative effects of intramuscular olanzapine in agitated patients

Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol

A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy

The impact of missing data and how it is handled on the rate of false-positive results in drug development

Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients

Intramuscular Olanzapine and Intramuscular Haloperidol in Acute Schizophrenia: Antipsychotic Efficacy and Extrapyramidal Safety during the First 24 Hours of Treatment

Evidence for Onset of Antipsychotic Effects Within the First 24 Hours of Treatment

Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials

Panel discussion 2

A Portfolio-Based Approach to Optimize Proof-of-Concept Clinical Trials

Bayesian adaptive non-inferiority with safety assessment: Retrospective case study to highlight potential benefits and limitations of the approach

Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol: Special Issue on Cognition in Schizophrenia: from basic science to clinical treatment

Influencing-Even Without Statistics

Statistical issues: a roundtable discussion

Practical Considerations for Building Priors for Confirmatory Studies

Suchergebnisse filtern